Publications by authors named "Nadia El Mouaddin"
Article Synopsis
- An evaluation compared the economic and clinical impact of mRNA-1273 versus BNT162b2 COVID-19 vaccines for immunocompromised individuals aged 30 and older in France during Fall 2023 and Spring 2024.
- * The study estimated outcomes like infections, hospitalizations, deaths, long COVID cases, costs, and quality-adjusted life years (QALYs) using a decision-analytic model, finding that mRNA-1273 vaccines offer greater protection.
- * In a scenario with full vaccine coverage, mRNA-1273 could prevent nearly 4,000 infections and 326 long COVID cases, resulting in €10.1 million in societal cost-savings and 645 additional QALYs.
Article Synopsis
- In October 2020, dostarlimab, a programmed death-1 inhibitor, was granted early access in France for treating advanced endometrial cancer based on the GARNET trial results and later approved by the European Medicines Agency in April 2021.
- A real-world analysis from November 2020 to June 2021 included data from 87 eligible patients who received at least one dose of dostarlimab, showcasing a disease control rate of 56% and an overall response rate of 35%, aligning with clinical trial findings.
- The study emphasized the urgent need for new treatment options for patients post-platinum in France and noted ongoing research into the efficacy and safety of dostarlim
Introduction: Head and neck cancers (HNC) accounted for over 450,000 deaths and 900,000 cases in 2018 worldwide. Of those, 38,000 cases were attributable to human papillomavirus (HPV). HNC is two to four times more prevalent in men than in women.
View Article and Find Full Text PDFObjectives: In France, 9-valent HPV vaccination is recommended routinely for 11-14-years-old girls and as catch-up for 15-19-years-old girls. Recently, recommendation for gender-neutral vaccination (GNV) has been approved. The objectives of the study were to assess the public health impact and cost-effectiveness of a 9-valent GNV compared with girls-only vaccination program (GOV).
View Article and Find Full Text PDFBackground: An infection with high-risk human papillomavirus (HPV) is the obligatory aetiological factor for the development of cervical cancer. In Switzerland, the prevention strategy for cervical cancer is based on primary prevention via HPV vaccination and secondary prevention with an opportunistic screening programme for precancerous lesions. Vaccination is recommended to 11-26 years old male and female persons.
View Article and Find Full Text PDF